Literature DB >> 14722660

[The initial dysphoric reaction (IDR) to the first dose of neuroleptics].

B Graf Schimmelmann1, M Schacht, C Perro, M Lambert.   

Abstract

Initial dysphoric response (IDR) is characterized by a negative affective reaction within 48 h after a neuroleptic test dose. Currently, there are three scales for measuring the IDR (Neuroleptic Dysphoria Scale, Dysphoric Response Index, Drug Attitude Inventory). The debate continues about the definition, measurement, and underlying aetiology of IDR. Nevertheless, with a prevalence of 30%, the response is a clinically relevant phenomenon. Empirical data give some evidence of an association between IDR and short-term outcome. No correlation of IDR with pretreatment variables has been found yet (e.g. age, gender, and psychopathology at baseline, especially depression and hostility). With respect to aetiology, a negative subjective reaction to concurrent extrapyramidal side effects and direct dysaffective effects of some neuroleptics have been discussed. Other studies found that IDR might not be a specifically antipsychotic effect. Our first results give some evidence that patients treated with atypical antipsychotics experience IDR less often and less severely than those treated with conventional antipsychotics described in the literature. Further research should include placebo-controlled studies and the evaluation of specific pretreatment variables. To assess the aetiology of IDR, further basic research is needed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722660     DOI: 10.1007/s00115-003-1544-z

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  42 in total

Review 1.  Neurobiology of addiction.

Authors:  R A Wise
Journal:  Curr Opin Neurobiol       Date:  1996-04       Impact factor: 6.627

2.  "Akinetic depression" in schizophrenia.

Authors:  T Van Putten; R P May
Journal:  Arch Gen Psychiatry       Date:  1978-09

3.  Early subjective response and prediction of outcome to neuroleptic drug therapy in schizophrenia.

Authors:  T P Hogan; A G Awad; M R Eastwood
Journal:  Can J Psychiatry       Date:  1985-06       Impact factor: 4.356

4.  Prediction of course and therapeutic response in psychiatric diseases.

Authors:  H Helmchen
Journal:  Pharmacopsychiatria       Date:  1983-11

5.  Prolonged adverse effects of haloperidol in normal subjects.

Authors:  B G Anderson; D Reker; T B Cooper
Journal:  N Engl J Med       Date:  1981-09-10       Impact factor: 91.245

6.  Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis.

Authors:  M M Singh; S R Kay
Journal:  Biol Psychiatry       Date:  1979-04       Impact factor: 13.382

7.  Neuroleptic-induced emotional defecation: effects of scopolamine and haloperidol.

Authors:  P R Sanberg; K H Russell; S H Hagenmeyer-Houser; M Giordano; E M Zubrycki; D L Garver
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  Predicting pharmacotherapy outcome by subjective response.

Authors:  E B Fink; W Braden; C B Qualls
Journal:  J Clin Psychiatry       Date:  1982-07       Impact factor: 4.384

9.  The prevalence of depressive symptoms and predisposing factors in an elderly Chinese population.

Authors:  J Woo; S C Ho; J Lau; Y K Yuen; H Chiu; H C Lee; I Chi
Journal:  Acta Psychiatr Scand       Date:  1994-01       Impact factor: 6.392

10.  Subjective response to antipsychotic drugs.

Authors:  T Van Putten; P R May; S R Marder; L A Wittmann
Journal:  Arch Gen Psychiatry       Date:  1981-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.